Annexon Inc. (ANNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANNX Stock Price Chart Interactive Chart >
ANNX Price/Volume Stats
| Current price | $7.14 | 52-week high | $8.43 |
| Prev. close | $7.10 | 52-week low | $2.06 |
| Day low | $6.77 | Volume | 832,796 |
| Day high | $7.26 | Avg. volume | 274,815 |
| 50-day MA | $5.77 | Dividend yield | N/A |
| 200-day MA | $4.91 | Market Cap | 340.08M |
Annexon Inc. (ANNX) Company Bio
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.
Latest ANNX News From Around the Web
Below are the latest news stories about ANNEXON INC that investors may wish to consider to help them evaluate ANNX as an investment opportunity.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to Dean “Rick” Artis, Ph.D., chief scientific officer, under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on January 4, |
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic FranchisesMid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical c |
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused PortfolioBRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Dean “Rick” Artis, Ph.D., has been appointed as chief scientific officer (CSO), succeeding Larry C. Mattheakis, Ph.D. Dr. Artis most recently served as CSO at Octant Bio and earlier, led efforts at Annex |
Annexon to Present at 41st Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco. A live webcast of |
Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
ANNX Price Returns
| 1-mo | 38.10% |
| 3-mo | 54.21% |
| 6-mo | 41.95% |
| 1-year | -4.80% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 38.10% |
| 2022 | -55.00% |
| 2021 | -54.10% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...